Mirimus

Diagnostics We build innovative diagnostic and monitoring tools that empower people to make better decisions about their health. 🧬 Drug Discovery We translate early-stage research into customized RNAi and CRISPR Cas9 animal and cell models to accelerate drug development. Therapeutics We identify and validate new drug targets, unleashing the commercial potential of RNAi to benefit people on a global scale. Established in 2010 to harness the power of RNAi and genetic engineering technologies developed by our founders in the labs of the world’s leading experts at Cold Spring Harbor Laboratory, Howard Hughes Medical Institute, and Harvard Medical School, Mirimus creates innovative research and clinical technologies to address health issues on a global scale. Today, Mirimus markets multiple unique and high-value drug discovery and diagnostic products and services, and is advancing a pipeline of therapeutic candidates in partnership with leading biopharma companies to create novel high-impact health care solutions that benefits society on a global scale. Mirimus’ ability to leverage its cutting-edge science and proprietary technology platforms to rapidly create new, affordable technology and products at scale is core to the way we work. We embrace diversity and creativity and have a proven track record of innovative problem solving—which led to our recognition as a $1M grand prize winner of the XPRIZE competition by developing a radically affordable, rapid, non-invasive methodology for mass COVID-19 testing—driving us to make better drugs and detect disease earlier. At Mirimus, our ingenuity, respect for our colleagues’ ideas and creativity, executional agility, and a commitment to global health equity combine to create a unique culture of innovation that delivers measurable progress.